Last reviewed · How we verify
Drug: INM004 Dose 1
Drug: INM004 Dose 1 is a Biologic drug developed by Inmunova S.A.. It is currently in Phase 1 development.
At a glance
| Generic name | Drug: INM004 Dose 1 |
|---|---|
| Sponsor | Inmunova S.A. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab')2 Fragment (INM004) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: INM004 Dose 1 CI brief — competitive landscape report
- Drug: INM004 Dose 1 updates RSS · CI watch RSS
- Inmunova S.A. portfolio CI
Frequently asked questions about Drug: INM004 Dose 1
What is Drug: INM004 Dose 1?
Drug: INM004 Dose 1 is a Biologic drug developed by Inmunova S.A..
Who makes Drug: INM004 Dose 1?
Drug: INM004 Dose 1 is developed by Inmunova S.A. (see full Inmunova S.A. pipeline at /company/inmunova-s-a).
What development phase is Drug: INM004 Dose 1 in?
Drug: INM004 Dose 1 is in Phase 1.
Related
- Manufacturer: Inmunova S.A. — full pipeline
- Compare: Drug: INM004 Dose 1 vs similar drugs
- Pricing: Drug: INM004 Dose 1 cost, discount & access